Telo Genomics Corp. TDSGF
0.03 USD 0.00 (+0.00%)
At closeNov 11, 2026, 4:00 PM EST
0.036 Day range 0.036
0.018 52-week range 0.065
- YTD
- -40.00%
- 1 year
- -28.57%
News
newsfilecorp.com Telo Genomics Announces $250,000 Term Loan Facility Non-dilutive secured term loan from BrightArc Capital to fund operating expenses. Vancouver, British Columbia--(Newsfile Corp. - November 6, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF)…
newsfilecorp.com TELO Genomics Expands Multi-Center Clinical Studies to Advance Comparative Validation of TELO-MRD Against Next-Generation Sequencing In matched multi-center cohorts, Telo Genomics is expanding comparative evaluation of blood-based TELO-MRD against Adaptive Biotechnologies' clonoSEQ next-generation sequencing MRD testing.…
newsfilecorp.com Telo Genomics Reports Additional Clinical Research Results Comparing Blood-Based TELO-MRD with Bone-Marrow Next-Generation Flow and Next-Generation Sequencing In matched Cleveland Clinic and Jewish General Hospital samples, blood-based TELO enumeration detected circulating plasma cells in all Adaptive clonoSEQ-positive cases reviewed and in a series of…
newsfilecorp.com Telo Genomics Announces Clinical Research Results Evidencing Utility of Its Telomere Analysis Platform in Predicting Multiple Myeloma Relapse Proprietary TeloView® blood-based TELO-MRD assay detected residual myeloma cells in a higher proportion of matched samples than bone-marrow next-generation flow cytometry in a University of Athens…
newsfilecorp.com Telo Genomics Grants Stock Options Vancouver, British Columbia--(Newsfile Corp. - August 4, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and…
newsfilecorp.com Telo Genomics Provides Positive Interim Data from Ongoing Clinical Trial Advancing Genomic Instability-Based Relapse Risk Assessment Clinical Study on Track to Meet Primary Endpoints with Interim Data Demonstrating Blood-Based Assay Capable of Predicting Relapse Risk Through Analysis of Genomic Instability and Telomere…
newsfilecorp.com Telo Genomics Files Patent to Expand IP Portfolio to Liquid Biopsy MRD Applications for Multiple Myeloma Toronto, Ontario--(Newsfile Corp. - July 9, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in diagnostic and prognostic innovation through advanced…
newsfilecorp.com Telo Genomics Announces Termination of Investor Relations Agreement Vancouver, British Columbia--(Newsfile Corp. - June 26, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and…
newsfilecorp.com Telo Genomics Announces Study with University of Athens to Advance Next-Generation MRD Risk Stratification in Multiple Myeloma Clinical Trial Seeks to Validate Novel Blood-Based Assay that Predicts Relapse Risk by Analyzing the Biologic Behavior of Remaining Cancer Cells, Addressing Critical Gaps in Current Minimal Residual…
newsfilecorp.com Telo Genomics Announces Appointment of John Farlinger as CEO and Chairman Vancouver, British Columbia--(Newsfile Corp. - March 31, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and…
newsfilecorp.com Telo Genomics Closes Second and Final Tranche of Convertible Debentures Financing Vancouver, British Columbia--(Newsfile Corp. - March 9, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and…
newsfilecorp.com Telo Genomics Corp. Announces Upsizing of Previously Announced Private Placement Vancouver, British Columbia--(Newsfile Corp. - February 27, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and…
newsfilecorp.com Telo Genomics Closes First Tranche of Convertible Debentures Financing THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, British Columbia--(Newsfile Corp. - February 18, 2026) - Telo Genomics Corp.…
newsfilecorp.com Telo Genomics Announces Appointment of John Price as Chief Financial Officer Toronto, Ontario--(Newsfile Corp. - January 29, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") a leader in the development of diagnostic and prognostic…
newsfilecorp.com Telo Genomics Announces Non-Brokered Private Placement of Convertible Debentures for up to $1,200,000 THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Toronto, Ontario--(Newsfile Corp. - January 19, 2026) - Telo Genomics Corp. (TSXV: TELO)…
newsfilecorp.com Telo Genomics Launches Retrospective Blood-Based MRD Study with University of Athens as Part of 2026 Multi-Center Validation Program Toronto, Ontario--(Newsfile Corp. - December 18, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in diagnostic and prognostic innovation through advanced…
newsfilecorp.com Telo Genomics Presents Genomic Profiles of Peripheral Blood Minimal Residual Disease Cells at the 67th American Society of Hematology Meeting Toronto, Ontario--(Newsfile Corp. - December 11, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for…
globenewswire.com Telo Genomics Corp to Present at the Small Cap Growth Virtual Investor Conference December 9th Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as…
newsfilecorp.com Telo Genomics to Present Groundbreaking Individual-Cell Risk Assessment MRD Technology at the Myeloma Canada MRD Implementation Summit 2025 Toronto, Ontario--(Newsfile Corp. - November 13, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) ("Telo" or the "Company"), a leader in diagnostic and prognostic innovation through its…
newsfilecorp.com American Society of Hematology Accepts Telo Genomics' Abstract for Presentation at its 2025 Meeting and Exposition Recognition highlights commercial potential of Telo's telomere-based MRD technology in the growing precision oncology market Toronto, Ontario--(Newsfile Corp. - October 9, 2025) - Telo Genomics Corp.…